Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cyclopharm Limited ( (AU:CYC) ) has provided an announcement.
Cyclopharm Limited has secured a five-year Federal Supply Schedule agreement with the US Veterans Health Administration, marking a significant expansion of its Technegas product within the US federal healthcare system. This agreement simplifies procurement processes and ensures a consistent supply of Technegas, strengthening Cyclopharm’s position in the US market despite uncertainties in healthcare funding policies.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that provides nuclear medicine solutions to the global medical community. The company’s primary product, Technegas, is used for functional lung ventilation imaging and has applications in diagnosing various pulmonary conditions.
YTD Price Performance: -17.41%
Average Trading Volume: 139,604
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$151.1M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.